Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.
Journal: Blood advances
Published: April 21, 2026
Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Journal: Blood advances
Published: April 21, 2026
Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.
Journal: Haematologica
Published: March 12, 2026
Baseline absolute lymphocyte count, C-reactive protein, and ferritin predict CAR T cell-related toxicities and outcomes in multiple myeloma.
Journal: Bone marrow transplantation
Published: January 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.
Journal: American journal of hematology
Published: October 28, 2025
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.
Journal: Blood cancer journal
Published: September 29, 2025
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
Journal: The New England journal of medicine
Published: August 20, 2025
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.
Journal: American journal of hematology
Published: July 30, 2025
Last Updated: 09/26/2026